EP0840739A4 - Ligands d'acide nucleique a haute affinite pour les lectines - Google Patents

Ligands d'acide nucleique a haute affinite pour les lectines

Info

Publication number
EP0840739A4
EP0840739A4 EP96923232A EP96923232A EP0840739A4 EP 0840739 A4 EP0840739 A4 EP 0840739A4 EP 96923232 A EP96923232 A EP 96923232A EP 96923232 A EP96923232 A EP 96923232A EP 0840739 A4 EP0840739 A4 EP 0840739A4
Authority
EP
European Patent Office
Prior art keywords
lectins
nucleic acid
high affinity
acid ligands
affinity nucleic
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP96923232A
Other languages
German (de)
English (en)
Other versions
EP0840739A1 (fr
Inventor
David H Parma
Brian Hicke
Philippe Bridonneau
Larry Gold
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Gilead Sciences Inc
Original Assignee
Gilead Sciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US08/479,724 external-priority patent/US5780228A/en
Priority claimed from US08/472,256 external-priority patent/US6001988A/en
Priority claimed from US08/472,255 external-priority patent/US5766853A/en
Application filed by Gilead Sciences Inc filed Critical Gilead Sciences Inc
Publication of EP0840739A1 publication Critical patent/EP0840739A1/fr
Publication of EP0840739A4 publication Critical patent/EP0840739A4/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6811—Selection methods for production or design of target specific oligonucleotides or binding molecules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
    • G01N2333/4701—Details
    • G01N2333/4724—Lectins
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/7056—Selectin superfamily, e.g. LAM-1, GlyCAM, ELAM-1, PADGEM
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/914—Hydrolases (3)
    • G01N2333/948—Hydrolases (3) acting on peptide bonds (3.4)
    • G01N2333/95—Proteinases, i.e. endopeptidases (3.4.21-3.4.99)
    • G01N2333/964—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue
    • G01N2333/96425—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals
    • G01N2333/96427—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals in general
    • G01N2333/9643—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals in general with EC number
    • G01N2333/96433—Serine endopeptidases (3.4.21)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Rheumatology (AREA)
  • Physics & Mathematics (AREA)
  • Oncology (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Analytical Chemistry (AREA)
  • Dermatology (AREA)
  • Neurosurgery (AREA)
  • General Engineering & Computer Science (AREA)
  • Communicable Diseases (AREA)
  • Biophysics (AREA)
  • Neurology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Transplantation (AREA)
  • Pain & Pain Management (AREA)
EP96923232A 1995-06-07 1996-06-05 Ligands d'acide nucleique a haute affinite pour les lectines Withdrawn EP0840739A4 (fr)

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
US47782995A 1995-06-07 1995-06-07
US479724 1995-06-07
US08/479,724 US5780228A (en) 1990-06-11 1995-06-07 High affinity nucleic acid ligands to lectins
US472255 1995-06-07
US08/472,256 US6001988A (en) 1990-06-11 1995-06-07 High affinity nucleic acid ligands to lectins
US08/472,255 US5766853A (en) 1990-06-11 1995-06-07 Method for identification of high affinity nucleic acid ligands to selectins
US477829 1995-06-07
PCT/US1996/009455 WO1996040703A1 (fr) 1995-06-07 1996-06-05 Ligands d'acide nucleique a haute affinite pour les lectines
US472256 1999-12-27

Publications (2)

Publication Number Publication Date
EP0840739A1 EP0840739A1 (fr) 1998-05-13
EP0840739A4 true EP0840739A4 (fr) 2006-02-01

Family

ID=27504168

Family Applications (1)

Application Number Title Priority Date Filing Date
EP96923232A Withdrawn EP0840739A4 (fr) 1995-06-07 1996-06-05 Ligands d'acide nucleique a haute affinite pour les lectines

Country Status (5)

Country Link
EP (1) EP0840739A4 (fr)
JP (2) JPH11507526A (fr)
AU (1) AU725590B2 (fr)
CA (1) CA2223275A1 (fr)
WO (1) WO1996040703A1 (fr)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK3440206T3 (da) * 2016-04-08 2020-11-23 Translate Bio Inc Multimer-kodende nukleinsyre og anvendelser deraf

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5270163A (en) * 1990-06-11 1993-12-14 University Research Corporation Methods for identifying nucleic acid ligands
WO1994009158A1 (fr) * 1992-10-14 1994-04-28 University Research Corporation Procede de selection d'acides nucleiques basee sur la structure
WO1996034876A1 (fr) * 1995-05-04 1996-11-07 Nexstar Pharmaceuticals, Inc. Complexes de ligands d'acide nucleique
US6280932B1 (en) * 1990-06-11 2001-08-28 Gilead Sciences, Inc. High affinity nucleic acid ligands to lectins

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5489677A (en) * 1990-07-27 1996-02-06 Isis Pharmaceuticals, Inc. Oligonucleoside linkages containing adjacent oxygen and nitrogen atoms
CA2104698A1 (fr) * 1991-02-21 1992-08-22 John J. Toole Aptameres specifiques de biomolecules et methodes de production
ATE245696T1 (de) * 1991-05-06 2003-08-15 Genentech Inc Ein selectin ligand

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5270163A (en) * 1990-06-11 1993-12-14 University Research Corporation Methods for identifying nucleic acid ligands
US6280932B1 (en) * 1990-06-11 2001-08-28 Gilead Sciences, Inc. High affinity nucleic acid ligands to lectins
US20030059769A1 (en) * 1990-06-11 2003-03-27 Parma David H. High affinity nucleic acid ligands to lectins
WO1994009158A1 (fr) * 1992-10-14 1994-04-28 University Research Corporation Procede de selection d'acides nucleiques basee sur la structure
WO1996034876A1 (fr) * 1995-05-04 1996-11-07 Nexstar Pharmaceuticals, Inc. Complexes de ligands d'acide nucleique

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
HICKE B J ET AL: "DNA aptamers block L-selectin function in vivo. Inhibition of human lymphocyte trafficking in SCID mice.", THE JOURNAL OF CLINICAL INVESTIGATION. 15 DEC 1996, vol. 98, no. 12, 15 December 1996 (1996-12-15), pages 2688 - 2692, XP002294403, ISSN: 0021-9738 *
O'CONNELL D ET AL: "Calcium-dependent oligonucleotide antagonists specific for L-selectin.", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA. 11 JUN 1996, vol. 93, no. 12, 11 June 1996 (1996-06-11), pages 5883 - 5887, XP002294404, ISSN: 0027-8424 *
See also references of WO9640703A1 *

Also Published As

Publication number Publication date
EP0840739A1 (fr) 1998-05-13
AU6450796A (en) 1996-12-30
JP2009039126A (ja) 2009-02-26
WO1996040703A1 (fr) 1996-12-19
CA2223275A1 (fr) 1996-12-19
JPH11507526A (ja) 1999-07-06
AU725590B2 (en) 2000-10-12

Similar Documents

Publication Publication Date Title
AU1310495A (en) Polyclonal antibody to pna/nucleic acid complexes
AU1039397A (en) Ligands to enhance cellular uptake of biomolecules
HUP9801949A3 (en) Ternary radiopharmaceutical complexes
AU6268598A (en) High affinity nucleic acid ligands of cd4
GB9518215D0 (en) Improvements relating to telecines
GB9408344D0 (en) Nucleic acid assays
GB9410805D0 (en) Biosensors
EP0840739A4 (fr) Ligands d'acide nucleique a haute affinite pour les lectines
GB9618880D0 (en) Improvements relating to trolleys
GB2297528B (en) Improvements relating to bicycles
GB9507723D0 (en) Improvements to brake blocks
ZA983900B (en) Process to 5-methyleneoxazolenes
GB9426105D0 (en) Improvements relating to electrolevels
GB9514852D0 (en) Improvements relating to cycle suspension systems
GB9523032D0 (en) Improvements to vehicles
GB9520213D0 (en) Improvements relating to spreading vehicles
GB8510090D0 (en) Vehicle parking vouchers
GB9504107D0 (en) Modifications to vehicle suspension
GB9415947D0 (en) Improvements relating to suspension systems
GB9415041D0 (en) Improvements relating to suspension systems
PL101079U1 (en) Laboratory terminal
PL101084U1 (en) Laboratory terminal
GB9401711D0 (en) Improvements relating to mocro-analytical techniques
GB9400734D0 (en) Improvements relating to connectors
GB9416336D0 (en) Improvement to bicycles

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 19971121

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE

RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: GILEAD SCIENCES, INC.

A4 Supplementary search report drawn up and despatched

Effective date: 20051220

GRAP Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOSNIGR1

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20100129